Clinical Trials in Barrett’s Esophagus: The SWAT-BE and SURVENT trials
Recorded April 25, 2023
Barrett’s Esophagus is the only known precursor of the most prevalent type of Esophageal Cancer in the US and other Western nations. Detection and treatment of this condition are key to preventing Esophageal Cancer. The only way to make progress in detecting and treating this disease is through research. During this webinar, we learn about two important clinical trials designed to improve the detection and treatment of Barrett’s Esophagus. The program is presented by Dr. Sachin Wani, Professor of Gastroenterology at the University of Colorado School of Medicine with commentary by Dr. Nicholas Shaheen, Chief of Gastroenterology and Hepatology at the Univerity of North Carolina School of Medicine, and Dr. Rhonda Souza, Co-Director of the Center for Esophageal Diseases and Co-Director of the Center for Esophageal Research at Baylor University Medical Center in Dallas and The Baylor, Scott and White Research Institute.
How Barrett’s Esophagus and Esophageal Cancer Can Run in Families
Recorded June 18, 2021
How Barrett’s Esophagus and Esophageal Cancer Can Run in Families. Amitabh Chak, MD is regarded as the research leader in Familial Links in Barrett’s Esophagus and EsophagealAdenocarcinoma and he shared the history of this research and his latest findings in the webinar. Dr. Chak is a Professor in the Department of Medicine, School of Medicine at Case Western Reserve University where he is a leader of the Cancer Genomics Program of the Case Comprehensive Cancer Center and the Digestive Health Research Institute. He has been a Principal Investigator for research funded by BETRNet (Barrett’s Esophagus Translational Research Network) of the National Cancer Institute. He is also a leader of the Advanced Technology and Innovation Center of University Hospitals at Cleveland Medical Center and Director of Clinical Research in the Department of Gastroenterology at University Hospitals Cleveland Medical Center.
Clinical Trial: PANGEA
(Personalized ANtibodies for GastroEsophageal Adenocarcinoma)
Recorded May 17, 2021
A Different Approach to Clinical Trials with Personalization Throughout. Daniel Catenacci, MD is Director of the Interdisciplinary Gastrointestinal Oncology Program at the University of Chicago Medical Center and Lead Investigator of the groundbreaking PANGEA (Personalized ANtibodies for GastroEsophageal Adenocarcinoma) study explains his approach to this clinical trial and the outcomes that benefitted patients. PANGEA provided patients with Advanced Esophageal Adenocarcinoma chemotherapy along with a targeted therapy chosen specifically for each patient based upon the genetics of their tumor and metastasis and adjusted the treatment provided based on new information gathered after the patients’ cancer progressed. Dr. Catenacci explains the strategy and outcomes of the study and answers questions from audience members. He also explores what his findings mean for the future of treatment for patients with Esophageal Cancer.
Deep Dive into Personalized Medicine in Esophageal Cancer
Recorded April 17, 2021
Learn about the Research that Supports First-Line Immunotherapy for Patients with Esophageal Cancer from the Distinguished Panel we have invited to share their experience, including Lead Investigators of those studies: Manish A. Shah, MD, Director, Gastrointestinal Oncology Program, Weill Cornell Medicine, New York, New York (Researcher on the study that led to the approval of Keytruda as a first-line therapy for patients with advanced Esophageal Cancer in combination chemotherapy), Yelena Y. Janjigian, MD, Chief, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York (Lead Researcher on the Checkmate-649 study that led to the FDA approval of Opdivo in combination with chemotherapy for patients with advanced gastroesophageal cancer), and Ronan J. Kelly, MD, MBA, Chief of Oncology for the 10 Baylor Scott & White Health’s North Texas Cancer Centers, Dallas, Texas (Lead Investigator of Checkmate-577, the large clinical trial that led to a change in the NCCN guidelines for patients who have undergone esophagectomy for Esophageal Cancer after chemoradiation but did not achieve a pathologic complete response.)
TRACK: Target -> Rare -> Cancer -> Knowledge
Recorded January 7, 2021
Join Jim Palma, Executive Director of the Target Cancer Foundation, to learn about TRACK, an innovative program for patients with rare cancers like Esophageal Cancer that allows patients to enroll from home and receivepersonalized, actionable genomic information about their cancer along with recommendations for on-label, off-label or clinical trial options that could inform their treatment plan. We’ll share all the details of this program and answer your questions!
A Pill-on-a-String Catches Esophageal Cancer Before it Starts
Recorded October 22, 2020
Join Dr. Rebecca Fitzgerald, Co-Leader of the Cancer Research UK Cambridge Institue Early Detection Programme and head of her own research lab where she developed the CytoSponge, a swallowable pill-sized capsule that can quickly detect Barrett’s Esophagus – without the sedation, risk, and cost that came with endoscopy. We’ll discuss her latest study that showed the CytoSponge increased detection of Barrett’s Esophagus ten-fold when compared to standard primary care.
Catching Esophageal Cancer Before It Starts
Recorded September 17th, 2020
Join Dr. Lishan Aklog, Co-Founder and CEO of PAVmed, the parent company of Lucid Diagnostics, maker of the new EsoGuard DNA test and EsoCheck device that can quickly and easily detect Barrett’s Esophagus – without barriers like sedation, risk, and cost that come with endoscopy. He’ll discuss the new landscape for early detection of Esophageal Cancer and explain how the EsoCheck works!
Esophageal Cancer and Its Impact on Mental Health
Recorded September 10th, 2020
What Causes Barrett’s Esophagus – Seeking a Path to Prevent Esophageal Cancer
Recorded August 6th, 2020
Nutrition and Esophageal Cancer
Recorded July 30, 2020
Join Oncology Dietitian Marissa Buchan, MS, RD, CSO, of Savor Health® to learn about nutrition strategies for Esophageal Cancer patients. We will also introduce a new opportunity for ECAN supporters: the Intelligent Nutrition Assistant: Ina®. ECAN has partnered with Savor Health® to bring personalized nutrition support to help those diagnosed with Esophageal Cancer eat healthily and stay well-nourished throughout treatment and beyond. We welcome your questions about nutrition in EC and about how Ina® might help you!
What Causes Barrett’s Esophagus to Become Esophageal Cancer?
Recorded June 23, 2020
Join Dr. Matthew Stachler, Principle Investigator and Molecular Genetic Pathologist at the University of California, San Francisco. We’ll discuss the latest discoveries about why Barrett’s becomes Cancer and the implications for prevention, early detection, and more effective treatment – and hopefully, answer your questions.
Immunotherapy in Esophageal Cancer
Recorded May 11, 2020
Join Dr. Daniel Catenacci, Director of the Interdisciplinary Gastrointestinal Oncology Program at the University of Chicago Medical Center. We’ll discuss immunotherapy in Esophageal Cancer and what may be possible in the future – and hopefully answer your questions.
Addressing GERD without Pills: Durable Approaches to Acid Reflux
Recorded April 30, 2020
Join ECAN’s Board Chair Dr. John C. Lipham, the Director of the Hoag-USC Foregut Cancer Program at the Keck Medical Center of the University of Southern California in Los Angeles, for a look at surgical approaches to reflux including fundoplication, LINX, and other newer approaches designed to produce a long-term impact on Gastroesophageal Reflux Disease (GERD).
Preventing Esophageal Cancer: Diagnosing and Treating Barrett’s Esophagus
Recorded April 28, 2020
ECAN Board Member Dr. Sri Komanduri, Medical Director, GI Lab, Director of Interventional Endoscopy, Northwestern University, Chicago discusses the latest methods for the diagnosis and treatment of Barrett’s Esophagus.
The Latest in Treatment for Esophageal Cancer
Recorded April 24, 2020
Dr. A. Craig Lockhart, Chief of Medical Oncology, Sylvester Comprehensive Cancer Center, Miami, FL, and Dr. Sarbajit Muhkerjee, Gastrointestinal Medical Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, both members of the ECAN Board of Directors, provide an overview of the latest treatment options available for patients diagnosed with Esophageal Cancer – and answer questions from ECAN President and CEO Mindy Mintz Mordecai and ECAN supporters.
Surgery & Survival in Esophageal Cancer
Recorded April 22, 2020
Dr. Stephen Yang, The Arthur B. and Patricia B. Modell Professor in Thoracic Surgery and medical oncology at Johns Hopkins Medicine and a founding Board member of the Esophageal Cancer Action Network joins ECAN CEO Mindy Mintz Mordecai for a look at Surgery and Survival in Esophageal Cancer. Dr. Yang provides an overview of the latest techniques for Esophageal Cancer surgery and answers participants’ questions.
Barrett’s Esophagus & Esophageal Adenocarcinoma can run in Families
Recorded April 21, 2020
Dr. Amitabh Chak of Case Western Reserve, the leading authority on Familial Links in Barrett’s and EAC, joins ECAN President and CEO Mindy Mintz Mordecai for a look at what the research shows and where he hopes the research will take us in the future.
Upcoming Webinar Information:
Please check back later for more details!